Analysis of homotypic and heterotypic serum immune responses to rotavirus proteins following primary rotavirus infection by using the radioimmunoprecipitation technique

Three sequential serum samples collected from each of 20 young children with a naturally acquired primary rotavirus infection were assayed by the radioimmunoprecipitation technique for immunoglobulin G antibodies to rotavirus structural and nonstructural proteins of the four major human rotavirus serotypes G1, P1A; G2, P1B; G3, P2; and G4, P2. Fourteen children were infected with a serotype G1 rotavirus strain and six children were infected with a serotype G4 rotavirus strain. Sera were collected from each child in the acute and convalescent periods postinfection and also approximately 4 months later. Serum immune responses to rotavirus core antigens VP2 and VP3, to the major inner capsid antigen VP6, to nonstructural proteins NS35, NS28, and NS26, and to the outer capsid neutralization antigen VP4 of all test strains were detected in the majority of patients. These responses do not appear to be influenced by the G type or P type of the rotavirus strain used in the reactions. Homologous responses to the main neutralization antigen VP7 were detected in 93% of patients with serotype G1 infections and 50% of patients with serotype G4 infections. Heterologous VP7 responses were less frequently detected and were restricted to G1, G3, and G4 serotype rotavirus strains. No responses to VP7 of the serotype G2 rotavirus strain were detected in any patients. Heterotypic immune responses to the neutralization antigens, at least following serotype G1 and G4 infections, therefore appear to consist primarily of responses to VP4 rather than to VP7.

[1]  R. Ward,et al.  Evidence that active protection following oral immunization of mice with live rotavirus is not dependent on neutralizing antibody. , 1992, Virology.

[2]  E. Mackow,et al.  Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. , 1990, The Journal of infectious diseases.

[3]  H. Greenberg,et al.  NS35 and not vp7 is the soluble rotavirus protein which binds to target cells , 1990, Journal of Virology.

[4]  R. Reves,et al.  An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children. Calculation of risk for second episodes using age-specific person-years of observation. , 1989, American journal of epidemiology.

[5]  R. Shaw,et al.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4 , 1989, Journal of clinical microbiology.

[6]  M. Vilar,et al.  Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants , 1989, Journal of clinical microbiology.

[7]  H. Greenberg,et al.  Molecular determinant of rotavirus neutralization and protection. , 1989, Advances in virus research.

[8]  R. Chanock,et al.  Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children. , 1988, The Journal of infectious diseases.

[9]  S. Plotkin,et al.  Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season , 1988, The Journal of infectious diseases.

[10]  R. Chanock,et al.  Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus , 1988, Journal of virology.

[11]  R. Ward,et al.  Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus , 1988, Journal of virology.

[12]  G. Barnes,et al.  Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children , 1988, Journal of clinical microbiology.

[13]  M. Estes,et al.  Identification of the simian rotavirus SA11 genome segment 3 product. , 1988, Virology.

[14]  H. Greenberg,et al.  The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Yolken,et al.  Epitope-specific immune responses to rotavirus vaccination. , 1987, Gastroenterology.

[16]  R. Chanock,et al.  Comparison of the amino acid sequences of the major neutralization protein of four human rotavirus serotypes. , 1987, Virology.

[17]  L. Unicomb,et al.  Simple and specific enzyme immunoassay using monoclonal antibodies for serotyping human rotaviruses , 1987, Journal of clinical microbiology.

[18]  E. Norrby,et al.  Serum antibody responses to individual viral polypeptides in human rotavirus infections. , 1987, The Journal of general virology.

[19]  G. Both,et al.  Gene cloning to study viral antigens: prospects for novel influenza and rotavirus vaccines. , 1987, Progress in veterinary microbiology and immunology.

[20]  H. Greenberg,et al.  Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype , 1986, Journal of virology.

[21]  K. Taniguchi,et al.  PROTECTIVE EFFECT OF NATURALLY ACQUIRED HOMOTYPIC AND HETEROTYPIC ROTAVIRUS ANTIBODIES , 1986, The Lancet.

[22]  R. Shaw,et al.  Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins vp3 and vp7 , 1986, Journal of virology.

[23]  P. Offit,et al.  Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies , 1985, Journal of virology.

[24]  R. Chanock,et al.  Reassortant rotaviruses as potential live rotavirus vaccine candidates , 1985, Journal of virology.

[25]  R. Lerner,et al.  Vaccines 85 : molecular and chemical basis of resistance to parasitic, bacterial, and viral diseases , 1985 .

[26]  D. Graham,et al.  Rotavirus antigens. , 1985, Advances in experimental medicine and biology.

[27]  G. Zissis,et al.  PROTECTION OF INFANTS AGAINST ROTAVIRUS DIARRHOEA BY RIT 4237 ATTENUATED BOVINE ROTAVIRUS STRAIN VACCINE , 1984, The Lancet.

[28]  R. Bishop,et al.  Cultivation of human rotaviruses in cell culture , 1984, Journal of medical virology.

[29]  G. Barnes,et al.  Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. , 1983, The New England journal of medicine.

[30]  R. Chanock,et al.  Antigenic characterization of human and animal rotaviruses by immune adherence hemagglutination assay (IAHA): evidence for distinctness of IAHA and neutralization antigens , 1981, Infection and immunity.

[31]  J. Chamberlain,et al.  Fluorographic detection of radioactivity in polyacrylamide gels with the water-soluble fluor, sodium salicylate. , 1979, Analytical biochemistry.

[32]  D. Snodgrass,et al.  Passive immunity in rotaviral infections. , 1978, Journal of the American Veterinary Medical Association.

[33]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[34]  J. Flores,et al.  Homotypic Serum Antibody Responses to Rotavirus Proteins following Primary Infection of Young Children with Serotype 1 Rotavirus , 2022 .